Neurocrine Biosciences, Inc. (NBIX) Stock Faces Lower Risks Forward After Forming Bullish Double Top Chart Pattern

December 7, 2017 - By Winifred Garcia

Investors sentiment increased to 1.25 in 2017 Q2. Its up 0.22, from 1.03 in 2017Q1. It increased, as 33 investors sold Neurocrine Biosciences, Inc. shares while 59 reduced holdings. 44 funds opened positions while 71 raised stakes. 91.92 million shares or 11.33% more from 82.57 million shares in 2017Q1 were reported.
Birchview Cap L P holds 25,200 shares or 0.61% of its portfolio. Td Asset Mngmt holds 0.01% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 156,600 shares. 216,562 were accumulated by Van Eck Associate Corp. Shell Asset Mngmt has 11,612 shares. Geode Management accumulated 716,391 shares. Redmile Grp Limited Liability invested in 0.02% or 6,640 shares. Sei Invests owns 106,389 shares. Rhenman And Prtnrs Asset Management reported 0.79% stake. Nationwide Fund has invested 0.02% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Ardsley Advisory Ptnrs stated it has 5,000 shares or 0.04% of all its holdings. Parametric Limited Liability has invested 0% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Marshall Wace Llp holds 10,093 shares. Btg Pactual Asset Management Limited has invested 0.14% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Peconic Ptnrs Ltd Liability Corporation accumulated 33,000 shares. The Sweden-based Nordea Investment has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

The chart of Neurocrine Biosciences, Inc. (NBIX) shows a double top with $77.58 target or 7.00 % above today’s $72.50 share price. The 9 months chart pattern indicates low risk for the $6.42B company. It was reported on Dec, 7 by If the $77.58 price target is reached, the company will be worth $449.12M more. Double tops are rare but powerful chart patterns.

The stock increased 3.85% or $2.69 during the last trading session, reaching $72.5. About 519,820 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 12.51% since December 7, 2016 and is uptrending. It has underperformed by 4.19% the S&P500.

Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on February, 13. They expect $-0.03 EPS, up 94.12 % or $0.48 from last year’s $-0.51 per share. After $-0.13 actual EPS reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts -76.92 % EPS growth.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 12 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 12 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci had 38 analyst reports since August 18, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, November 14 by Oppenheimer. The company was initiated on Tuesday, November 22 by Oppenheimer. As per Thursday, August 3, the company rating was maintained by BMO Capital Markets. On Friday, October 27 the stock rating was maintained by Cowen & Co with “Buy”. As per Wednesday, October 25, the company rating was maintained by Piper Jaffray. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Monday, September 25 by Cowen & Co. The rating was maintained by Oppenheimer on Thursday, November 2 with “Buy”. H.C. Wainwright maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Thursday, November 2 with “Buy” rating. As per Thursday, November 2, the company rating was maintained by Leerink Swann. Leerink Swann maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating on Tuesday, October 10. Leerink Swann has “Buy” rating and $72.0 target.

More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: which released: “Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT …” on December 04, 2017, also with their article: “Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer” published on November 20, 2017, published: “Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare …” on November 21, 2017. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: and their article: “Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for …” published on November 29, 2017 as well as‘s news article titled: “Neurocrine Biosciences to Present at the BMO Capital Markets 2017 …” with publication date: December 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.